Sugi Predict

Sugi Predict / Compounds / SCHEMBL842961

SCHEMBL842961

SCHEMBL842961

Nc1cc(=O)nc(SCc2ccccc2)[nH]1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.65
▸ MAPT P10636 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ GFER P55789 1/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ HTT P42858 1/20 0.57
▸ MAOB P27338 1/20 0.55
▸ CXCR2 P25025 1/20 0.53
▸ HPGD P15428 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ XDH P47989 1/20 0.51
▸ DAO P14920 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CTSB P07858 3/20 0.49
▸ TOP2A P11388 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5331447 0.82 MAPT (0.61) SCN9AMAPTPKMTSHRGFER
SCHEMBL22639950 0.74 MAPT (0.57) MAPTTSHRSMN1; SMN2ALDH1A1KMT2A
SCHEMBL143289 0.73 ALDH1A1 (0.50) SCN9AMAPTPKMTSHRGFER
SCHEMBL18063501 0.73 HPGD (0.73) SCN9AMAPTPKMTSHRGFER
SCHEMBL6110139 0.72 SMN1; SMN2 (0.58) SCN9AMAPTPKMTSHRGFER
SCHEMBL27765163 0.72 HPGD (0.73) SCN9AMAPTPKMTSHRGFER
SCHEMBL12820638 0.71 SCN9A (0.56) SCN9AMAPTPKMTSHRGFER
SCHEMBL13977445 0.70 SMN1; SMN2 (0.69) SCN9AMAPTPKMTSHRGFER
SCHEMBL841338 0.70 CXCR2 (0.66) SCN9AMAPTPKMTSHRGFER
SCHEMBL7509964 0.70 SMN1; SMN2 (0.63) SCN9AMAPTPKMTSHRGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222922-A1 RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) THE JOHNS HOPKINS UNIVERSITY (US) 2018-08-09 — — US disclosed
US-20180222922-A1 RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) THE JOHNS HOPKINS UNIVERSITY (US) 2018-08-09 — — US disclosed
WO-2016200939-A1 RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-15 — — WO disclosed
US-8143261-B2 Thiazolo (4,5-D) pyrimidine compounds ASTRAZENECA AB (SE) 2012-03-27 — — US disclosed
US-20090281123-A1 NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS ASTRAZENECA UK LIMITED 2009-11-12 — — US disclosed
US-7579342-B2 Pteridine compounds for the treatment of psoriasis ASTRAZENECA (SE) 2009-08-25 — — US disclosed
EP-1348709-B1 Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis ASTRAZENECA UK LTD (GB) 2008-01-16 — — EP disclosed
US-6958343-B2 Thiazolopyrimidines and their use as modulators of chemokine receptor activity ASTRAZENECA, AB (SE) 2005-10-25 — — US disclosed
US-20050171345-A1 Pteridine compounds for the treatment of psoriasis ASTRAZENECA AB, A SWEDEN CORPORATION 2005-08-04 — — US disclosed
US-6875868-B2 Pteridine compounds for the treatment of psoriasis ASTRAZENECA AB (SE) 2005-04-05 — — US disclosed
US-20030032642-A1 Thiazolopyrimidines and thier use as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2003-02-13 — — US disclosed
EP-1104425-B1 NOVEL THIAZOLOPYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2003-01-29 — — EP disclosed
EP-1259512-A1 PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS AstraZeneca AB (SE) 2002-11-27 — — EP disclosed
EP-1257556-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2002-11-20 — — EP disclosed
EP-1222195-A1 NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS AstraZeneca UK Limited (GB) 2002-07-17 — — EP disclosed
WO-2001062758-A1 PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS ASTRAZENECA AB (SE) 2001-08-30 — — WO disclosed
WO-2001058907-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-08-16 — — WO disclosed
EP-1104425-A1 NOVEL THIAZOLOPYRIMIDINE COMPOUNDS AstraZeneca AB (SE) 2001-06-06 — — EP disclosed
WO-2001025242-A1 NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2001-04-12 — — WO disclosed
WO-2000009511-A1 NOVEL THIAZOLOPYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2000-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222922-A1 RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) CX3CR1, CXCR3, CXCR5 SCN9A 3629/4885MAPT 3626/4885PKM 1519/4885
US-20030032642-A1 Thiazolopyrimidines and thier use as modulators of chemokine receptor activity CCR5, CCR2, CXCR4 SCN9A 4432/4885MAPT 3667/4885PKM 1791/4885
US-20090281123-A1 NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS TYMS, DPYD, TPMT SCN9A 2704/4885MAPT 1022/4885PKM 1187/4885
US-20050171345-A1 Pteridine compounds for the treatment of psoriasis DHFR, NAMPT, HPRT1 SCN9A 4010/4885MAPT 1267/4885PKM 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.